|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 9/16 | |
| A61K 9/20 | |||
| A61K 31/496 |
| (11) | Patento numeris | 2588086 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11734043.0 |
| Europos patento paraiškos padavimo data | 2011-06-29 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-05-08 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2018-09-12 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2011/060949 |
| Data | 2011-06-29 |
| (87) | Numeris | WO 2012/001074 |
| Data | 2012-01-05 |
| (30) | Numeris | Data | Šalis |
| 10168028 | 2010-06-30 | EP |
| (72) |
THAKUR, Jeewan, CH
QIU, Zhihui, CN
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTATE MONOHYDRATE. |
| PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTATE MONOHYDRATE. |